证券代码：000504 证券简称：南华生物 公告编号：2023-057 南华生物医药股份有限公司 第十一届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 南华生物医药股份有限公司（以下简称"公司"）第十一届董事会第十七次 会议于2023年11月27日以通讯方式召开。会议通知于2023年11月22日以邮件、短 信方式送达公司全体董事。会议应参与表决董事7名，实际参与表决董事7名。会 议召开符合《公司法》及《公司章程》等的有关规定，合法有效。 1 《关于控股公司拟减少注册资本的议案》 同意厦门城光新能源有限公司在保证日常经营所需资金的前提下，根据自身 经营发展的需要，将注册资本由人民币5,000万元减少至人民币400万元。 表决结果：会议以7票赞成，0票反对，0票弃权，审议通过了《关于控股公 司拟减少注册资本的议案》 二、董事会议案审议情况 具体内容详见公司于同日披露的《关于控股公司拟减少注册资本的公告》， 独立董事对该事项发表同意的独立意见。 三、备查文件 经与会董事签字并盖章的相关董事会决议。 特此公告。 ...

根据《上市公司治理准则》《上市公司独立董事管理办法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等法律、法规和规范性文件规定和《南华生物医药股份有限公司章 程》等相关规定，作为南华生物医药股份有限公司（以下简称"公司"）的独立 董事，我们认真审阅了公司第十一届董事会第十七次会议的会议材料，经审慎分 析，本着认真、负责、独立判断的态度，现对公司第十一届董事会第十七次会议 的相关事项发表独立意见如下： 公司根据控股公司厦门城光的实际经营情况，结合其业务发展现状，对其注 册资本予调整，符合公司整体发展规划，有利于公司资源的合理调配，提升资产 运营效率，符合公司利益，不存在损害公司和股东利益的情形。 南华生物医药股份有限公司 独立董事：醋卫华 赵亚青 赵 南华生物医药股份有限公司 独立董事关于第十一届董事会第十七次会议相关事项的独立意见 平 2023 年 11 月 27 日 1 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥34,326,150.54, a decrease of 26.38% compared to the same period last year, and a cumulative revenue of ¥104,759,853.14, down 33.02% year-on-year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥9,459,873.30, an increase of 681.72% year-on-year, while the cumulative net profit was ¥486,718.30, a decrease of 9.99%[5]. - The basic and diluted earnings per share for Q3 2023 were both ¥0.0304, reflecting a significant increase of 684.62% compared to the same period last year[5]. - Total operating revenue for Q3 2023 was ¥104,759,853.14, a decrease of 32.98% compared to ¥156,404,576.30 in the same period last year[22]. - Net profit for Q3 2023 was ¥4,709,236.40, a decline of 42.56% compared to ¥8,159,911.17 in Q3 2022[24]. - The company reported a basic and diluted earnings per share of ¥0.0016 for Q3 2023, compared to ¥0.0017 in the previous year[24]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥542,187,740.19, a decrease of 1.97% from the end of the previous year[5]. - Total assets as of Q3 2023 amounted to ¥542,187,740.19, a slight decrease from ¥553,064,727.36 at the end of the previous period[20]. - Total liabilities decreased to ¥457,594,303.92 from ¥473,180,527.49, reflecting a reduction of 3.43%[20]. - The company's total liabilities decreased by 39.56% in short-term borrowings, amounting to ¥38,126,871.29[10]. - The company's non-current assets totaled ¥122,739,211.11, down from ¥136,828,754.20, indicating a decrease of 10.29%[20]. Cash Flow - The company’s cash flow from operating activities decreased by 84.32% to ¥20,424,564.32 year-to-date[5]. - Operating cash flow for the current period is ¥20,424,564.32, a decrease of 84.3% compared to ¥130,252,235.42 in the previous period[26]. - Total cash inflow from operating activities is ¥155,278,948.10, down 50% from ¥310,456,290.99 year-on-year[26]. - The company’s cash flow from operating activities is impacted by a significant reduction in cash received from sales, which decreased to ¥141,635,801.14 from ¥172,792,521.72[26]. - Cash flow from investment activities shows a net inflow of ¥12,500,503.93, compared to a net outflow of ¥20,892,052.90 in the previous period[27]. - Cash inflow from investment activities totals ¥424,144,822.76, significantly up from ¥138,063,913.25 in the previous period[27]. - Cash outflow from financing activities is ¥60,813,352.83, down from ¥138,579,523.05 in the previous period[27]. - The company’s cash and cash equivalents at the end of the period stand at ¥218,230,076.45, compared to ¥188,825,485.09 at the end of the previous period[27]. - The company received ¥28,000,000.00 from borrowings, down 56.9% from ¥65,040,000.00 in the previous period[27]. - The company paid ¥53,036,250.00 in debt repayments, an increase of 51.5% compared to ¥35,000,000.00 in the previous period[27]. Inventory and Investments - The company’s inventory increased by 61.58% to ¥7,272,355.80, primarily due to the addition of raw materials and inventory goods[10]. - Accounts receivable increased to 162,608,054.37 RMB from 158,759,054.35 RMB at the start of the year[18]. - Inventory rose to 7,272,355.80 RMB, up from 4,500,707.82 RMB at the beginning of the year[18]. - The company’s long-term equity investments slightly decreased to 5,479,883.06 RMB from 5,484,304.54 RMB[18]. - The company reported a significant increase in investment income of 656.15%, amounting to ¥787,244.74, compared to a loss of ¥141,553.29 in the previous year[11]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,982[13]. - The largest shareholder, Hunan Caixin Industrial Fund Management Co., holds 25.58% of shares, totaling 79,701,655 shares[13]. - The company has no preferred shareholders as of the reporting date[15]. Future Plans and Developments - The company plans to raise up to 276 million RMB through a private placement of A-shares to its controlling shareholder[15]. - The company plans to focus on market expansion and new product development to drive future growth[20]. - The company has ongoing research and development expenses of ¥6,938,971.61, slightly up from ¥6,895,486.58 year-on-year, indicating continued investment in innovation[22]. - The company has not disclosed any new product or technology developments in this report[15]. Tax and Other Income - The company reported a significant reduction in income tax expenses, down 76.05% to ¥1,160,896.78, due to decreased income tax from subsidiaries[11]. - The company’s other income decreased by 65.80% to ¥1,396,589.58, mainly due to a reduction in government subsidies received[11]. Audit Status - The company has not undergone an audit for the third quarter report[28].

证券代码：000504 证券简称：南华生物 公告编号：2023-055 南华生物医药股份有限公司 第十一届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 南华生物医药股份有限公司（以下简称"公司"）第十一届监事会第十一次 会议于2023年10月30日以通讯方式召开。会议通知于2023年10月23日以邮件、短 信方式送达公司全体监事。会议应参与表决监事3名，实际参与表决监事3名。会 议召开符合《公司法》及《公司章程》的有关规定，合法有效。 二、监事会议案审议情况 经审核，公司监事会认为：董事会编制和审议《2023年第三季度报告》的程 序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映 了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：会议以3票赞成，0票反对，0票弃权，审议通过了《关于<2023年 第三季度报告>的议案》。 具体内容详见同日披露的《2023年第三季度报告》。 三、备查文件 经与会监事签字并盖章的监事会决议。 特此公告。 南华生物医药股份有限公司监 ...

证券代码：000504 证券简称：南华生物 公告编号：2023-054 南华生物医药股份有限公司 第十一届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 南华生物医药股份有限公司（以下简称"公司"）第十一届董事会第十六次 会议于2023年10月30日以通讯方式召开。会议通知于2023年10月23日以邮件、短 信方式送达公司全体董事。会议应参与表决董事7名，实际参与表决董事7名。会 议召开符合《公司法》及《公司章程》等的有关规定，合法有效。 表决结果：会议以7票赞成，0票反对，0票弃权，审议通过了《关于<2023年 第三季度报告>的议案》。 具体内容详见公司于同日披露的《2023年第三季度报告》。 三、备查文件 经与会董事签字并盖章的相关董事会决议。 特此公告。 南华生物医药股份有限公司董事会 2023 年 10 月 31 日 1 二、董事会议案审议情况 《关于<2023年第三季度报告>的议案》 公司《2023年第三季度报告》符合《证券法》及《深圳证券交易所股票上市 规则》及定期报告格式等的有关规定，能充分反 ...

二、本次交易的进展 近日，公司收到相关不动产权登记证书，本次转让的 2 处房产已完成过户登 记手续，相关房产已过户至湖南国投名下。至此，公司将不再持有以上 2 处房产。 三、备查文件 证券代码：000504 证券简称：南华生物 公告编号：2023-053 南华生物医药股份有限公司 关于通过公开挂牌方式转让自有房产的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、本次交易的概述 为盘活闲置资产，优化资产结构，提高资产运营效率，南华生物医药股份有 限公司（以下简称"公司"）分别于 2023 年 8 月 6 日、2023 年 8 月 25 日召开 了第十一届董事会第十四次会议和 2023 年第二次临时股东大会，审议通过了《关 于拟通过公开挂牌方式转让自有房产的议案》，同意公司通过公开挂牌方式在湖 南省联合产权交易所有限公司（以下简称"湖南联交所"）转让位于海南省海口 市的 2 处自有房产，挂牌底价参考评估结果确定为 2,097.60 万元；经湖南联交 所征集，湖南省国有投资经营有限公司（以下简称"湖南国投"）成为合格竞买 人；2023 年 9 月 2 ...

证券代码：000504 证券简称：南华生物 公告编号：2023-052 南华生物医药股份有限公司 关于参加2023年湖南辖区上市公司投资者网上集体接待日活动 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，南华生物医药股份有限公司(以下简称 “公司”)将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公 司联合举办的“推动上市公司规范运作，保护中小投资者——2023 年湖南辖区 上市公司投资者网上集体接待日”活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录“全景路演”网站 (https://rs.p5w.net),或关注微信公众号：全景财经，或下载全景路演APP,参 与本次互动交流，活动时间为2023 年 11月 2 日(星期四)15:30-17:00。届时公 司将在线就公司经营状况、发展战略等投资者关心的问题，与投资者进行沟通与 交流，欢迎广大投资者踊跃参与！ ...

证券代码：000504 证券简称：南华生物 公告编号：2023-051 南华生物医药股份有限公司 关于通过公开挂牌方式转让自有房产的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、本次交易的概述 为盘活闲置资产，优化资产结构，提高资产运营效率，南华生物医药股份有 限公司（以下简称"公司"）分别于 2023 年 8 月 6 日、2023 年 8 月 25 日召开 了第十一届董事会第十四次会议和 2023 年第二次临时股东大会，审议通过了《关 于拟通过公开挂牌方式转让自有房产的议案》，同意公司通过公开挂牌方式在湖 南省联合产权交易所有限公司（以下简称"湖南联交所"）转让位于海南省海口 市的 2 处自有房产，挂牌底价参考评估结果确定为 2,097.60 万元。具体内容详 见公司于 2023 年 8 月 8 日在法定媒体披露的《关于拟通过公开挂牌方式转让自 有房产的公告》（公告编号：2023-042）。 二、本次交易的进展 近日，公司收到湖南联交所出具的《电子竞价成交确认书》，挂牌期满，征 集到 1 家意向受让方，经审查，最终确定湖南省国有投资经营有限 ...

的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 南华生物医药股份有限公司（以下简称"公司"）于2023年8月29日收到中 国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意南华生物 医药股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕1930号） （以下简称"批复"），批复主要内容如下： 证券代码：000504 证券简称：南华生物 公告编号：2023-050 南华生物医药股份有限公司 关于向特定对象发行股票申请获得中国证监会同意注册批复 公司董事会将根据上述文件和相关法律法规的要求及公司股东大会的授权， 在规定期限内办理本次向特定对象发行股票的相关事宜，并及时履行信息披露义 务。敬请广大投资者注意投资风险。 特此公告。 南华生物医药股份有限公司董事会 2023 年 8 月 30 日 1 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送深圳证券交易所的申报文件和发行方案 实施。 三、本批复自同意注册之日起12个月内有效。 四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及时 报告深 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥70,433,702.60, a decrease of 35.84% compared to ¥109,777,202.11 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was a loss of ¥8,973,155.00, representing a decline of 514.10% from a profit of ¥2,166,923.99 in the previous year[20]. - The net cash flow from operating activities was ¥9,218,256.99, down 91.72% from ¥111,323,801.11 in the same period last year[20]. - The basic and diluted earnings per share were both -¥0.0288, a decrease of 511.43% compared to ¥0.0070 in the previous year[20]. - The weighted average return on equity was -96.65%, a decline of 108.88% from 12.23% in the previous year[20]. - Total assets at the end of the reporting period were ¥550,657,787.87, a decrease of 0.44% from ¥553,064,727.36 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were ¥4,798,048.62, down 65.16% from ¥13,771,203.62 at the end of the previous year[20]. Revenue Breakdown - The company achieved a total operating revenue of 70.43 million yuan, with the biopharmaceutical segment contributing 54.30 million yuan, a year-on-year decline of 23.13%[32]. - The environmental protection segment generated 15.92 million yuan in revenue, representing a significant year-on-year decrease of 59.31%[32]. - The revenue from the energy-saving technology services segment dropped by 59.31% to ¥15,923,116.90, down from ¥39,133,603.95[45]. - The biopharmaceutical segment generated ¥54,304,734.92, a decrease of 23.13% from ¥70,643,598.16, accounting for 77.10% of total revenue[45]. - Revenue from cell storage and testing reached CNY 53,439,347.9, reflecting a 73.99% increase year-over-year, with a gross margin of 30.34%[47]. Cash Flow and Expenses - The company reported a significant decrease in cash generated from operating activities, which fell by 91.72% to ¥9,218,256.99 from ¥111,323,801.11 in the prior year[42]. - The investment activities generated a cash outflow of ¥1,435,599.81, an improvement of 88.20% from a cash outflow of ¥12,167,727.29 in the previous year[42]. - The company’s income tax expense decreased by 83.42% to ¥415,923.53 from ¥2,507,956.88, mainly due to reduced income tax from subsidiaries[42]. - Research and development expenses remained stable at ¥4,360,387.52, a slight increase of 0.47% compared to ¥4,339,826.77 in the previous year[42]. Market and Industry Insights - The global stem cell market was valued at approximately 17.9 billion yuan in 2022, projected to reach 37.2 billion yuan by 2029, with a CAGR of 10.9% from 2023 to 2029[28]. - China's stem cell market revenue reached 967 million USD in 2021, expected to grow to 3.03 billion USD by 2028, with a CAGR of 17.92% from 2022 to 2028[28]. - The environmental protection industry in China is expected to maintain a growth rate of 15-20% during the 14th Five-Year Plan period[29]. Strategic Initiatives - The company is actively involved in the development of stem cell research and applications, supported by local government initiatives to promote innovation and commercialization in the biopharmaceutical sector[34]. - The company aims to enhance its capabilities in gene therapy, stem cell therapy, and immunotherapy, aligning with national policies that emphasize the importance of these technologies in the biopharmaceutical industry[35]. - The company is focused on expanding its market presence in regenerative medicine, with strategic support from provincial and national regulatory bodies to facilitate clinical research and product development[34]. - The company is committed to achieving a 13.5% reduction in energy consumption per unit of GDP by 2025, in line with national energy efficiency goals[35]. Risks and Challenges - The company faces a risk of reduced potential customer base as the national birth rate has been declining, with rates of 8.52‰, 7.52‰, and 6.77‰ over the past three years[66]. - The company is exposed to regulatory and policy risks, particularly in the cell storage and treatment sectors, which are subject to high levels of scrutiny and evolving regulations[67]. - The competitive landscape in the energy-saving and environmental protection industry is intensifying, with many new entrants and increasing pressure from established players[68]. - The company is at risk of fluctuating gross margins and declining net profits, which could lead to a decrease in net assets if business performance does not stabilize[69]. Legal Matters - The company is involved in a lawsuit with a claim amount of 1,242.04 million yuan, which has not yet formed a liability[91]. - Another lawsuit involves a claim of 1,973.51 million yuan, which is currently pending trial[91]. - The company has reported a total of 101,322 yuan in litigation costs related to the aforementioned lawsuits[91]. Shareholder Information - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 25.58% of the shares, totaling 79,701,655 shares[119]. - The second largest shareholder, Shanghai Peaceful Large Equity Investment Fund Management Co., Ltd., holds 11.43% of the shares, totaling 35,600,000 shares[119]. - The company has a total of 14,689 shareholders at the end of the reporting period[118]. Financial Statements and Compliance - The company's financial statements were approved for release on August 29, 2023[166]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position, operating results, and cash flows accurately[172]. - The company includes all subsidiaries under its control in the consolidated financial statements, prepared according to the relevant accounting standards[178].